Mass spectrometry

The COVID-19 antiviral race: we’re all in this together By Uduak Grace Thomas Volume 21 Issue 3 – Summer 2020 In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop […]

Thermo Scientific iCAP PRO Series ICP-OES instruments capture a complete spectrum in a single measurement for high matrix samples. Scientists no longer need to limit routine trace element analysis workflow productivity with the launch of a new series of inductively coupled plasma optical emission spectroscopy (ICP-OES) instruments for food and beverage, consumer safety, industrial, environmental […]

Thermo Fisher Scientific will provide online programming and virtual exhibits to introduce scientists to a number of new products that build on its leading Orbitrap platform and expand research applications. The company said it will showcase its newest instruments, software and workflow solutions during a company-hosted virtual event, vLC-MS.com, on May 26 -28, 2020, and at […]

Image: Pille-Riin Priske Avacta has begun work with the UK government’s CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry (BAMS) laboratory assay developed with Adeptrix. The COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR), recently funded by the National Institute for Health Research, UK Research and Innovation, Asthma UK […]

Share Share Tweet Email Could marine alga be a remedy against infections and skin cancer? Could marine alga be a remedy against infections and skin cancer? 6 July 2020 Image: Shane Stagner Marine organisms and their microbial symbionts are invaluable sources of new medicines for human diseases. Natural products from the sea have four times […]

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 – Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and cancer has never been greater. […]

By Dr William Olds and Dr Deepa Shankar While the antibody market has evolved into a multibillion-dollar industry enabling the discovery of cures, disease diagnosis and basic science acceleration, this has allowed low quality antibodies to hit the market. With a large crisis in reproducibility, the need for high quality antibodies has never been greater. […]

Innovative glycan imaging methods drive cancer biomarker discovery By Dr Richard Drake, Dr Anand Mehta and Dr Peggy Angel Volume 21 Issue 2 – Spring 2020 Glycosylation accounts for the majority of post-translational modifications (PTMs) of proteins, and changes in glycosylation are known to play a key role in disease state. Novel mass spectrometry (MS) […]

Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased healthcare interventions, from the increased […]

The Future Of Drug Discovery – Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds, acting alone or in combination, […]